Nuvectis Pharma, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nuvectis Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2021 to 2023.
  • Nuvectis Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$4.15M, a 29.4% increase year-over-year.
  • Nuvectis Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$19.4M, a 13.3% increase year-over-year.
  • Nuvectis Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.3M, a 16.6% decline from 2022.
  • Nuvectis Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$19.1M, a 48.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$22.3M -$3.18M -16.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$19.1M -$6.2M -48.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$12.9M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.